CTI BioPharma (CTIC) PT Raised to $7.20 at Brookline Capital Markets
Tweet Send to a Friend
Brookline Capital Markets analyst Leah Rush Cann raised the price target on CTI BioPharma (NASDAQ: CTIC) to $7.20 (from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
